MWMargaret Weiss

Margaret Weiss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Margaret Weiss has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A randomized controlled trial of CBT therapy for adults with ADHD with and without medication

    by Margaret Weiss, Candice Murray, Michael Wasdell, Brian Greenfield, Lauren Giles, Lily Hechtman

    Previous studies of psychological treatment in adults with ADHD have not controlled for medication status and include either medicated participants or mixed samples of medicated and unmedicated participants. The objective of this study is to examine whether use of medication improves outcome of therapy. This was a secondary analysis comparing 23 participants randomized to CBT and Dextroamphetamine vs. 25 participants randomized to CBT and placebo. Both patients and investigators were blind to treatment assignment. Two co-primary outcomes were used: ADHD symptoms on the ADHD-RS-Inv completed by the investigator and improvement in functioning as reported by the patient on the Sheehan Disability Scale. Both groups showed robust improvement in both symptoms and functioning, but the use of medication did not significantly improve outcome over and above use of CBT and placebo. This study replicates previous work demonstrating that CBT is an effective treatment for ADHD in adults. Within the limits of this pilot, secondary analysis we were not able to demonstrate that medication significantly augments the outcome of CBT therapy for adults with ADHD. The study was funded by GlaxoSmithKline, Clinical Trials Registry #GSK707.


  • Useful websites for ADHD (in alphabetical order)

    by Jan K. Buitelaar, Cornelis C. Kan, Philip J. Asherson, Leonard A. Adler, Henrik Anckarsäter, L. Eugene Arnold, Russell Barkley, Joseph Biederman, Andrew D. Blackwell, Jessica Bramham, et al.

    Although the phenomenon of ADHD (Attention-Deficit Hyperactivity Disorder) is well described in children, it is now thought that in up to 60% of cases the symptoms persist into adulthood. This volume reviews our growing knowledge of adult ADHD and presents a transatlantic perspective on the identification, assessment and treatment of the disorder. The introductory section covers the history of ADHD, as well as the epidemiology, consequences, gender differences and legal aspects. Detailed descriptions of the clinical features of ADHD in adults are then given to enhance the reader's clinical recognition and assessment. Subsequent sections cover treatment strategies, emphasising pharmacological, psychological and social interventions. Written and edited by experts internationally renowned for their work in ADHD, this is an essential resource for all mental health workers who encounter adults presenting with neurodevelopmental disorders.

  • Open Access

    A Naturalistic Study of Predictors and Risks of Atypical Antipsychotic Use in an Attention-Deficit/Hyperactivity Disorder Clinic

    by Margaret Weiss, Constadina Panagiotopoulos, Lauren Giles, Christopher Gibbins, Boris Kuzeljevic, Jana Davidson, Rebecca Harrison

    Objective: This was an exploratory study to examine the use of atypical antipsychotics in an attention-deficit/hyperactivity disorder (ADHD) clinic. Method: A total of 194 patients was examined to compare those receiving atypical or second-generation antipsychotics (atypicals) from those who were not. A sample of 27 children on atypicals received laboratory investigation for indicators of possible metabolic effects. Results: In all, 19.1% of the patients in the clinic were receiving atypicals with a mean duration of 313 days; 36 of 37 patients on atypicals had received risperidone, with a mean dose of 0.62 mg. Children receiving atypicals were statistically more likely to have a severe co-morbid disorder, a lower Children's Global Assessment Scale score, a greater total score on the teacher Strengths and Difficulties Questionnaire, and greater difficulty with parent-rated symptoms of being touchy, worried, rages, and explosive outbursts. There were no differences found in measures of functioning, adaptive skills, quality of life, or ADHD symptoms. In the subset of children studied for potential metabolic effects, 68.0% had a waist circumference ≥90 th percentile that was independent of weight gain, 18.5% had impaired fasting glucose, 12.5% had elevated blood pressure, 11.1% had elevated triglycerides, and 16.7% met full criteria for metabolic syndrome. Conclusion: Clinical implementation of the efficacy studies of risperidone for disruptive behavior disorders has led to a significant change in practice. Almost 1 in 5 patients are now receiving atypical neuroleptics, typically to treat severe co-morbid disorders and symptoms other than ADHD per se . Despite these children receiving low doses, concomitant stimulants, and low body mass index z -scores, a significant proportion of children demonstrated either one or more components or the full criteria for metabolic syndrome.


    • 1 January 2006
      • p. 38-45

    Effectiveness outcomes in attention-deficit/hyperactivity disorder.

    by Margaret D Weiss, Kenneth Gadow, Michael B Wasdell

    Attention-deficit/hyperactivity disorder (ADHD) is common, chronic, and associated with significant functional impairment. It is highly treatable. It is therefore not only a major public health problem but also one that provides a unique opportunity in medicine to make a significant difference. This article will discuss the methodology needed to demonstrate empirically the impact of treatment on actual burden of illness in practice. Where efficacy studies demonstrate whether a treatment can work, effectiveness studies tell us whether they actually do work. Clinical trials exclude incompetent, non-compliant, and seriously comorbid patients, so that the information obtained from these trials tells us the most about the patients we see the least. Small differences in effect size in pivotal trials of efficacy have become a key variable for rating treatments as first line or second line, without consideration of effectiveness variables such as comorbidity, difficulty with appetite or sleep, patient preference, capacity for compliance, timing of functional impairment, and substance use. These effectiveness variables are less well studied, but critical to clinical decision making. In reality, fewer than 10% of our patients comply with and persist with treatment. To learn more about why patients are discontinuing treatment, we need to explore measures of effectiveness empirically. Effectiveness studies are also important to provide regulatory bodies with the data they need to balance the risk of treatment with the risk of failing to treat. Practical clinical trials and naturalistic follow-up studies will allow us to evaluate the true clinical impact of short-term efficacy trials.